Understanding O
marijuana O
’ O
s O
effects O
on O
functional O
connectivity O
of O
the O
default O
mode O
network O
in O
patients O
with O
schizophrenia O
and O
co-occurring O
cannabis O
use O
disorder O
: O
A O
Pilot O
Investigation O
Nearly O
half O
of O
patients O
with O
schizophrenia O
( O
SCZ O
) O
have O
co-occurring O
cannabis O
use O
disorder O
( O
CUD O
) O
, O
which O
has O
been O
associated O
with O
decreased O
treatment O
efficacy O
, O
increased O
risk O
of O
psychotic O
relapse O
, O
and O
poor O
global O
functioning O
. O

While O
reports O
on O
the O
effects O
of O
cannabis O
on O
cognitive O
performance O
in O
patients O
with O
SCZ O
have O
been O
mixed O
, O
study O
of O
brain O
networks O
related O
to O
executive O
function O
may O
clarify O
the O
relationship O
between O
cannabis O
use O
and O
cognition O
in O
these O
dual-diagnosis O
patients O
. O

In O
the O
present O
pilot O
study O
, O
patients O
with O
SCZ O
and O
CUD O
( O
n=12 O
) O
and O
healthy O
controls O
( O
n=12 O
) O
completed O
two O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
resting O
scans O
. O

Prior O
to O
the O
second O
scan O
, O
patients O
smoked O
a O
3.6 O
% O
tetrahydrocannabinol O
( O
THC O
) O
cannabis O
cigarette O
or O
ingested O
a O
15mg O
delta-9-tetrahydrocannabinol O
( O
THC O
) O
pill O
. O

We O
used O
resting-state O
functional O
connectivity O
to O
examine O
the O
default O
mode O
network O
( O
DMN O
) O
during O
both O
scans O
, O
as O
connectivity/activity O
within O
this O
network O
is O
negatively O
correlated O
with O
connectivity O
of O
the O
network O
involved O
in O
executive O
control O
and O
shows O
reduced O
activity O
during O
task O
performance O
in O
normal O
individuals O
. O

At O
baseline O
, O
relative O
to O
controls O
, O
patients O
exhibited O
DMN O
hyperconnectivity O
that O
correlated O
with O
positive O
symptom O
severity O
, O
and O
reduced O
anticorrelation O
between O
the O
DMN O
and O
the O
executive O
control O
network O
( O
ECN O
) O
. O

Cannabinoid O
administration O
reduced O
DMN O
hyperconnectivity O
and O
increased O
DMN-ECN O
anticorrelation O
. O

Moreover O
, O
the O
magnitude O
of O
anticorrelation O
in O
the O
controls O
, O
and O
in O
the O
patients O
after O
cannabinoid O
administration O
, O
positively O
correlated O
with O
WM O
performance O
. O

The O
finding O
that O
DMN O
brain O
connectivity O
is O
plastic O
may O
have O
implications O
for O
future O
pharmacotherapeutic O
development O
, O
as O
treatment O
efficacy O
could O
be O
assessed O
through O
the O
ability O
of O
therapies O
to O
normalize O
underlying O
circuit-level O
dysfunction O
. O

Experimental O
Materials O
and O
Methods O
Subjects O
Twelve O
patients O
with O
SCZ O
and O
CUD O
and O
twelve O
healthy O
control O
subjects O
participated O
in O
this O
study O
. O

As O
previously O
described O
in O
all O
patients O
were O
recruited O
from O
community O
mental O
health O
centers O
and O
met O
criteria O
for O
SCZ O
and O
CUD O
, O
defined O
as O
either O
current O
cannabis O
abuse O
or O
dependence O
with O
use O
within O
the O
past O
month O
prior O
to O
study O
enrollment O
, O
as O
determined O
by O
the O
Structured O
Clinical O
Interview O
for O
DSM-IV-TR O
( O
SCID O
) O
. O

While O
a O
history O
of O
alcohol O
or O
substance O
use O
( O
other O
than O
cannabis O
) O
was O
permitted O
in O
the O
patient O
group O
, O
they O
were O
required O
to O
be O
alcohol O
and O
substance O
free O
for O
a O
minimum O
of O
seven O
days O
prior O
to O
testing O
and O
scanning O
. O

Tobacco O
users O
were O
included O
in O
the O
study O
, O
since O
up O
to O
90 O
% O
of O
patients O
with O
SCZ O
smoke O
cigarettes O
. O

All O
patients O
were O
on O
a O
stable O
dose O
of O
antipsychotic O
medication O
for O
a O
minimum O
of O
one O
month O
prior O
to O
study O
participation O
. O

Patients O
taking O
clozapine O
were O
excluded O
given O
its O
proposed O
ability O
to O
decrease O
alcohol O
and O
cannabis O
use O
in O
patients O
with O
SCZ O
. O

Pharmacotherapies O
for O
addiction O
, O
mental O
retardation O
, O
a O
history O
of O
head O
injury O
, O
or O
factors O
that O
contraindicate O
the O
use O
of O
fMRI O
served O
as O
exclusion O
criteria O
. O

The O
healthy O
control O
group O
was O
matched O
to O
the O
patient O
sample O
on O
age O
, O
gender O
and O
handedness O
. O

In O
addition O
to O
the O
exclusion O
criteria O
noted O
above O
, O
controls O
were O
excluded O
if O
they O
had O
any O
current O
or O
history O
of O
Axis O
I O
or O
II O
disorders O
, O
including O
any O
substance O
use O
disorder O
. O

A O
signed O
informed O
consent O
was O
obtained O
from O
participants O
prior O
to O
initiation O
of O
the O
study O
. O

The O
protocol O
was O
approved O
by O
the O
Committee O
for O
the O
Protection O
of O
Human O
Subjects O
( O
IRB O
) O
at O
Dartmouth O
College O
. O

Further O
details O
of O
the O
study O
design O
were O
reviewed O
in O
. O

Study O
Design O
and O
Procedure O
Participants O
refrained O
from O
substance O
use O
( O
except O
for O
tobacco O
or O
caffeine O
) O
for O
the O
duration O
of O
the O
study O
. O

Subjects O
completed O
a O
‘ O
baseline O
’ O
session O
( O
T1 O
) O
, O
and O
then O
returned O
one O
week O
later O
for O
a O
second O
scan O
session O
( O
T2 O
) O
during O
which O
patients O
were O
randomized O
to O
one O
of O
two O
double-blinded O
cannabinoid O
intervention O
groups O
: O
an O
oral O
THC O
group O
( O
N=6 O
) O
or O
an O
active O
cannabis O
cigarette O
( O
3.6 O
% O
THC O
) O
group O
( O
N=6 O
) O
. O

Those O
in O
the O
THC O
group O
were O
given O
a O
15mg O
THC O
pill O
( O
three O
hours O
prior O
to O
scanning O
) O
and O
then O
smoked O
a O
placebo O
cannabis O
cigarette O
immediately O
prior O
to O
scanning O
. O

Those O
in O
the O
cannabis O
group O
were O
given O
a O
placebo O
pill O
( O
3 O
hours O
prior O
to O
scanning O
) O
and O
then O
smoked O
an O
active O
3.6 O
% O
THC O
cannabis O
cigarette O
immediately O
before O
scanning O
. O

Smoking O
took O
place O
in O
a O
smoking O
chamber O
within O
the O
scanner O
bay O
, O
immediately O
prior O
to O
scanning O
( O
Figure O
1a O
) O
. O

Patients O
who O
were O
tobacco O
smokers O
were O
asked O
to O
smoke O
a O
cigarette O
90 O
minutes O
prior O
to O
scanning O
, O
based O
upon O
pharmacokinetics O
of O
smoked O
tobacco O
. O

Further O
details O
can O
be O
found O
in O
. O

Healthy O
control O
participants O
followed O
the O
same O
study O
protocol O
, O
but O
did O
not O
receive O
any O
pharmacologic O
intervention O
during O
T2 O
. O

In O
order O
to O
assist O
patients O
in O
remaining O
abstinent O
from O
substance O
use O
for O
the O
duration O
of O
the O
study O
, O
they O
were O
assessed O
three O
times O
in O
the O
week O
prior O
to O
each O
scan O
session O
. O

Each O
time O
, O
they O
were O
screened O
for O
substance O
use O
with O
an O
alcohol O
breathalyzer O
, O
a O
Timeline O
Follow-Back O
interview O
, O
and O
a O
urine O
toxicology O
screen O
( O
ToxCup O
Drug O
Screen O
cup O
; O
CLIAwaived O
, O
Sand O
Diego O
, O
CA O
) O
. O

Patients O
were O
discontinued O
from O
the O
study O
if O
screening O
suggested O
substance O
use O
during O
study O
participation O
. O

THC O
and O
symptom O
measures O
Venous O
blood O
samples O
were O
collected O
from O
patients O
at O
T1 O
, O
in O
the O
morning O
of O
the O
T2 O
session O
, O
immediately O
prior O
to O
fMRI O
scanning O
, O
and O
before O
cognitive O
testing O
( O
Figure O
1b O
) O
. O

The O
Marijuana O
Craving O
Questionnaire O
( O
MCQ O
) O
, O
Cannabis O
Withdrawal O
Scale O
( O
CWS O
) O
, O
and O
Positive O
and O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
were O
administered O
to O
assess O
for O
change O
in O
marijuana O
craving O
, O
withdrawal O
, O
and O
positive O
and O
negative O
symptoms O
. O

Change O
in O
these O
measures O
was O
analyzed O
using O
repeated O
measures O
analysis O
of O
variance O
( O
ANOVA O
) O
with O
group O
as O
the O
between O
group O
factor O
and O
time O
as O
the O
within-subjects O
factor O
, O
followed O
by O
post-hoc O
analysis O
using O
Tukey O
’ O
s O
LSD O
test O
for O
pairwise O
comparisons O
. O

Working O
memory O
performance O
To O
assess O
for O
change O
in O
working O
memory O
performance O
induced O
by O
cannabis O
and O
THC O
, O
the O
Wechsler O
Adult O
Intelligence O
Scale O
( O
WAIS O
) O
III O
Letter O
Number O
Sequencing O
Test O
was O
administered O
approximately O
30 O
minutes O
after O
the O
end O
of O
the O
scanning O
sessions O
at O
T1 O
and O
T2 O
. O

This O
test O
was O
selected O
because O
of O
availability O
of O
alternate O
forms O
and O
thus O
its O
applicability O
to O
the O
repeated-measures O
study O
design O
. O

The O
change O
in O
WM O
performance O
in O
patients O
was O
evaluated O
with O
a O
repeated-measures O
ANOVA O
. O

A O
correlation O
analysis O
between O
WM O
performance O
and O
the O
magnitude O
of O
DMN-ECN O
anticorrelation O
was O
performed O
between O
the O
MPFC O
component O
of O
the O
DMN O
and O
the O
DLPFC O
component O
of O
the O
ECN O
. O

fMRI O
data O
acquisition O
fMRI O
data O
were O
obtained O
using O
a O
3T O
Phillips O
Achieva O
fMRI O
scanner O
with O
an O
8 O
channel O
head O
coil O
. O

Each O
subject O
underwent O
two O
8-minute O
resting O
scans O
during O
the O
study O
with O
eyes O
open O
, O
one O
at O
baseline O
( O
T1 O
) O
, O
and O
the O
second O
during O
the O
‘ O
intervention O
’ O
session O
( O
T2 O
) O
. O

Further O
details O
can O
be O
found O
in O
. O

The O
resting O
state O
data O
were O
acquired O
transverse O
to O
the O
AC-PC O
plane O
, O
with O
a O
T2 O
* O
-weighted O
single O
shot O
echo O
planar O
imaging O
( O
EPI O
) O
pulse O
sequence O
designed O
to O
measure O
whole O
brain O
BOLD O
contrast O
with O
optimal O
temporal O
and O
spatial O
resolution O
[ O
repetition O
time O
( O
TR O
) O
=2000ms O
; O
echo O
time O
( O
TE O
) O
=30ms O
; O
Flip O
angle O
( O
FA O
) O
=90 O
degrees O
; O
field O
of O
view O
( O
FOV O
) O
=240 O
mm O
; O
Slice O
thickness=2.5 O
mm O
; O
Slice O
skip O
0.5 O
; O
Slice O
location=Pat O
. O

Spec O
; O
Fat O
saturation=SPIR O
; O
Reps=240 O
; O
NEX=1 O
; O
yielding O
36 O
contiguous O
transverse O
functional O
images O
in O
an O
80×80 O
matrix O
with O
an O
isotropic O
resolution O
of O
3.0 O
mm3 O
] O
. O

T1-weighted O
anatomic O
reference O
images O
were O
acquired O
in O
the O
same O
planes O
and O
thickness O
immediately O
following O
the O
resting O
scans O
. O

fMRI O
data O
analysis O
Resting O
state O
data O
were O
analyzed O
using O
a O
seed O
driven O
approach O
( O
http O
: O
//www.nitrc.org/projects/conn O
) O
. O

We O
used O
methods O
that O
minimize O
the O
influence O
of O
motion O
and O
artifact O
and O
that O
allow O
for O
valid O
identification O
of O
correlated O
and O
anticorrelated O
networks O
. O

Data O
were O
slice O
time O
corrected O
, O
realigned O
, O
coregistered O
, O
normalized O
, O
and O
spatially O
smoothed O
with O
a O
6-mm O
kernel O
. O

To O
address O
the O
spurious O
correlations O
in O
resting-state O
networks O
caused O
by O
head O
motion O
we O
used O
quality O
assurance O
software O
Artifact O
Detection O
Tools O
( O
http O
: O
//www.nitrc.org/projects/artifact_detect O
; O
http O
: O
//www.nitrc.org/projects/conn O
) O
to O
identify O
problematic O
time O
points O
during O
the O
scan O
. O

Specifically O
, O
an O
image O
was O
defined O
as O
an O
outlier O
if O
the O
head O
displacement O
in O
x O
, O
y O
, O
or O
z O
direction O
was O
greater O
than O
.5mm O
from O
the O
previous O
frame O
, O
or O
if O
the O
global O
mean O
intensity O
in O
the O
image O
was O
greater O
than O
3 O
standard O
deviations O
from O
the O
mean O
image O
intensity O
for O
the O
entire O
resting O
scan O
. O

A O
single O
regressor O
for O
each O
outlier O
image O
was O
included O
in O
the O
first O
level O
general O
linear O
model O
along O
with O
motion O
parameters O
and O
first O
order O
derivatives O
. O

Physiological O
and O
other O
spurious O
sources O
of O
noise O
were O
estimated O
and O
regressed O
using O
the O
anatomical O
CompCor O
method O
( O
aCompCor O
) O
as O
opposed O
to O
global O
signal O
regression O
, O
a O
widely O
used O
preprocessing O
method O
known O
to O
artificially O
introduce O
negative O
correlations O
. O

The O
anatomical O
image O
for O
each O
participant O
was O
segmented O
into O
white O
matter O
, O
grey O
matter O
, O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
masks O
using O
SPM8 O
. O

To O
minimize O
partial O
voluming O
with O
grey O
matter O
, O
the O
white O
matter O
and O
CSF O
masks O
were O
eroded O
by O
one O
voxel O
, O
which O
resulted O
in O
substantially O
smaller O
masks O
than O
the O
original O
segmentations O
. O

The O
eroded O
white O
matter O
and O
CSF O
masks O
were O
then O
used O
as O
noise O
regions O
of O
interest O
( O
ROI O
) O
. O

Signals O
from O
the O
white O
matter O
and O
CSF O
noise O
ROIs O
were O
extracted O
from O
the O
unsmoothed O
functional O
volumes O
to O
avoid O
additional O
risk O
of O
contaminating O
white O
matter O
and O
CSF O
signals O
with O
grey O
matter O
signals O
. O

Previous O
results O
showed O
that O
aCompCor O
signals O
were O
considerably O
different O
from O
the O
global O
signal O
, O
as O
regressing O
higher O
order O
principal O
components O
of O
the O
global O
signal O
diminished O
both O
positive O
and O
negative O
correlations O
whereas O
regressing O
aCompCor O
signals O
resulted O
in O
stronger O
anticorrelations O
and O
eliminated O
spurious O
correlations O
. O

Based O
on O
previous O
results O
, O
five O
principal O
components O
of O
the O
signals O
from O
white O
matter O
and O
CSF O
noise O
ROIs O
were O
removed O
with O
regression O
. O

A O
temporal O
band-pass O
filter O
of O
0.009 O
Hz O
to O
0.08 O
Hz O
was O
applied O
to O
the O
time O
series O
. O

The O
residual O
BOLD O
time-series O
was O
band-pass O
filtered O
over O
a O
low-frequency O
window O
of O
interest O
( O
0.009Hz O
< O
f O
< O
0.08Hz O
) O
. O

Correlation O
maps O
were O
produced O
by O
extracting O
the O
residual O
BOLD O
time O
course O
from O
seed O
regions O
based O
on O
the O
literature O
. O

The O
DMN O
seed O
was O
defined O
using O
a O
10 O
mm O
sphere O
around O
peak O
MPFC O
coordinates O
, O
as O
specified O
in O
. O

Pearson O
’ O
s O
correlation O
coefficients O
were O
then O
calculated O
between O
the O
DMN O
time O
course O
and O
the O
time O
course O
of O
all O
other O
voxels O
in O
the O
brain O
. O

Correlation O
coefficients O
were O
converted O
to O
normally O
distributed O
scores O
using O
Fisher O
’ O
s O
transformation O
to O
allow O
for O
second-level O
General O
Linear O
Model O
analyses O
. O

Second-level O
within-group O
( O
one O
sample O
t-tests O
) O
and O
between O
group O
( O
ANOVA O
) O
analyses O
were O
performed O
on O
the O
Z-maps O
from O
the O
MPFC O
. O

Correction O
for O
multiple O
comparisons O
on O
analyses O
were O
implemented O
with O
an O
FDR O
correction O
of O
p O
< O
0.001 O
. O

